Bei Akademie registrieren
UCB, BE0003739530

UCB stock pre-market at EUR 204.05: biopharma group overview

Published on 10/19/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The Belgian biopharmaceutical company focuses on neurological and immunological medicines. At Lang & Schwarz, UCB stock trades pre-market at EUR 204.05 on October 19, 2026.

Business focus before trading

  • UCB develops medicines for neurological and immunological diseases.
  • The investor-relations page carries an October 16, 2026 update date.
  • UCB stock trades pre-market at EUR 204.05 at 7:40 a.m. CEST at Lang & Schwarz on October 19, 2026.
Schwarzweiß-Reportagefoto einer Wissenschaftlerin bei der Untersuchung einer Petrischale im Labor
UCB S.A. (BE0003739530) dokumentarisch: authentische Schwarzweiß-Reportage einer Wissenschaftlerin bei sorgfältiger Laboranalyse mit Petrischale, Illustration mit AI erstellt.

UCB develops medicines for neurological and immunological diseases. On October 19, 2026, UCB stock traded pre-market at EUR 204.05 at 7:40 a.m. CEST at Lang & Schwarz.

Ahead of the Xetra open

The pre-market indication was recorded before the regular Xetra session. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of UCB stock.

UCB's business and investor calendar

UCB researches and develops medicines for neurological and immunological diseases and generates revenue from its marketed therapies. The company's investor-relations page was last updated on October 16, 2026.

Market context: Market report Euro Stoxx 50.

More news and analysis on UCB stock

Disclaimer...
en | BE0003739530 | UCB | boerse | 70357439 | bgmi